Food and Drug Administration

Transmissible Spongiform Encephalopathies Advisory Committee

February 13, 2004


Current CBER Safeguards for Blood Products: Approach to Products Containing or Exposed to Bovine Materials, Dr. Dorothy Scott, MD, FDA (HTM) (PPT)

FDA Recommended Safeguards for Minimizing Risk of vCJD From Blood Products: Deferral of Donors Based on Risk of BSE Exposure, Dr. Alan Williams, PhD, FDA (HTM) (PPT)

Minimizing the Risks of TSE Agents in Human Tissues, Dr. Melissa Greenwald, MD, FDA (HTM) (PPT)

Bovine-Derived Products Used in the Manufacture and Formulation of Vaccines and Allergenic Products: Minimizing TSE Risks, Dr. William Egan, PhD, FDA (HTM) (PPT)

Minimizing the Risk of TSE in CDER-Regulated Products, Dr. Gerald Feldman, PhD, FDA (HTM) (PPT)

CDRH: Minimizing Risk of TSE Agents in Medical Devices, Martha O'Lone, RN, BSN, FDA (HTM)(PPT)